Keywords: Teva, CureTech, Collaboration terminated, CT-011, Cancer drug, Alzheimer's, AC Immune, Ph II, ACI-91
Teva pulls out of CureTech deal; AC Immune drops CI-91
Article | 01 February 2013
Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration with CureTech for the development of an ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
